CP01-R01 – CKD in companion animals
Pivotal Ph 3 Trial in Canine with CKD to Evaluate CP01's Renal Efficacy
First oral endothelial stabilizer–based candidate for companion animal CKD therapy
Currently in Phase 3 clinical trial in dogs, with potential application in cats
Demonstrated renal protection by preserving endothelial function and reducing inflammation and fibrosis
Prevalence & Market Context
CKD affects up to 10% of elderly dogs
Prevalence reaches 35–60% in senior cats
Rising pet healthcare market highlights a strong unmet need for effective CKD therapies
Oral formulation enables convenient long-term administration → positioned as a new treatment option for veterinary CKD